Protective Effects of Simvastatin, a Lipid Lowering Agent, against Oxidative Damage in Experimental Diabetic Rats

Table 3

Effect of simvastatin (SMV) and glibenclamide supplementation on blood glucose, haemoglobin (Hb) and glycosylated haemoglobin (HbA1_c) of rats in different experimental groups.

Groups	Blood glucose (mg/dL)	Hb (g/dL)	HbA1c (% Hb)
Control	84.3 ± 4.2	12.8 ± 0.41	5.8 ± 0.32
SMV	87.5 ± 3.6	13.0 ± 0.36	6.1 ± 0.21
Diabetic	336 ± 9.8*	9.8 ± 0.43*	12.7 ± 0.5*
Diabetic + SMV	260 ± 7.3^*#	10.6 ± 0.52	10.2 ± 0.33^*#
Diabetic + Glibenclamide	127.5 ± 6.4^*#	12.3 ± 0.48^#	6.7 ± 0.03^#

Data are the mean ± SEM for eight animals in each group.
* 𝑃<0.001 compared with the control group.
^#𝑃<0.05 compared with the untreated diabetic group.